Jazz Pharmaceuticals (JAZZ) PT Raised to $277 at RBC Capital
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $277.00 (from $273.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
